Sinoright International Trade Co., Ltd.
Main products:Brushless Electric Screwdriver ( Chemical Machinery),Wrap Film,Vitamins,Fine Chemical,Dyestuff,Food Additive&feed Additive,Pharmaceutical Raw Materials
Contact Us
  • Contact Person : Mr. Du Harry
  • Company Name : Sinoright International Trade Co., Ltd.
  • Tel : 0086-411-39210844
  • Fax : 0086-411-39210855
  • Address : Liaoning,Dalian,106# Taihua Building B Area Free Tax ZOne Dalian
  • Country/Region : China
  • Zip : 116600


Product Detailed
Related Categories:Organic Intermediate
Related Product Searches:Urapidil,High Quality,Urapidil, Urapidil HCl price,usp
Urapidil HCl High Quality Earliest shipment Competitive price Professional Service

Urapidil HCl

Urapidil HCl

High Quality

Earliest shipment

Competitive price

Professional Service

Urapidil is a sympatholytic antihypertensive drug. It acts as an α1-adrenoceptor antagonist and as an 5-HT1A receptor agonist[1] Although an initial report suggested that urapidil was also an α2-adrenoceptor agonist,[2] this was not substantiated in later studies that demonstrated it was devoid of agonist actions in the dog saphenous vein and the guinea-pig ileum.[3] Unlike some other α1-adrenoceptor antagonists, urapidil does not elicit reflex tachycardia, and this may be related to its weak β1-adrenoceptor antagonist activity,[4][5] as well as its effect on cardiac vagal drive [6] Urapidil is currently not approved by the U.S. Food and Drug Administration, but it is available in Europe.


Despite the availability of a wide range of effective blood pressure (BP)-lowering agents, a substantial proportion of patients with hypertension fail to achieve target BP levels. The majority of patients with hypertension need a combination of two or more drugs to achieve BP targets and choice of second-line or subsequent-line therapy is an important consideration in hypertension management. Alpha-1-adrenoreceptor antagonists (alpha-blockers) have a BP-lowering effect broadly similar to the other antihypertensive drug classes and are effective as add-on therapy in patients with inadequately controlled hypertension. Alpha-blockers may also have therapeutic benefits that go beyond BP control, including improvements in lipid profile and glucose metabolism, as well as reducing the symptoms of benign prostatic hyperplasia. Urapidil has an alpha-blocking effect but, unlike other alpha-blockers, also has a central sympatholytic effect mediated via stimulation of serotonin 5HT(1A) receptors in the central nervous system. Several studies have suggested that oral urapidil is effective and well tolerated when used as second-line therapy in patients with BP inadequately controlled with other agents. Urapidil has also been shown to improve glucose and lipid metabolism in hypertensive patients with concomitant diabetes and/or hyperlipidemia. Intravenous urapidil is effective in the treatment of hypertensive crises, perioperative hypertension, and pre-eclampsia and may have a potential role in the management of acute stroke. In this review, the use of alpha-blockers in hypertension is discussed, with particular focus on urapidil for the lowering of BP in a variety of clinical settings.


Copyright Notice @ 2008-2012 ECVERY Limited and/or its subsidiaries and licensors. All rights reserved.